[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sciences Inc (WVE)

Wave Life Sciences Inc (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 994,107
  • Shares Outstanding, K 197,048
  • Annual Sales, $ 42,730 K
  • Annual Income, $ -204,380 K
  • EBIT $ -218 M
  • EBITDA $ -209 M
  • 60-Month Beta -1.26
  • Price/Sales 27.99
  • Price/Cash Flow N/A
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 149.00% (+2.09%)
  • Historical Volatility 68.19%
  • IV Percentile 91%
  • IV Rank 52.30%
  • IV High 229.17% on 06/16/26
  • IV Low 61.11% on 07/20/26
  • Expected Move (DTE 9) 0.50 (9.57%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 619
  • Volume Avg (30-Day) 813
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 28,434
  • Open Int (30-Day) 25,695
  • Expected Range 4.74 to 5.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 5
  • High Estimate $-0.29
  • Low Estimate $-0.36
  • Prior Year $-0.32
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +4.59%
on 08/11/26
6.41 -18.25%
on 08/10/26
-1.01 (-16.16%)
since 07/10/26
3-Month
5.01 +4.59%
on 08/11/26
7.14 -26.66%
on 05/14/26
-1.55 (-22.83%)
since 05/12/26
52-Week
5.01 +4.59%
on 08/11/26
21.73 -75.89%
on 12/09/25
-3.21 (-37.99%)
since 08/12/25

Most Recent Stories

More News
Wave Life Sciences Announces Completion of Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 5.24 (+3.87%)
Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 5.24 (+3.87%)
Wave Life Sciences: Q2 Earnings Snapshot

Wave Life Sciences: Q2 Earnings Snapshot

WVE : 5.24 (+3.87%)
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dosing underway in  Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also...

WVE : 5.24 (+3.87%)
Wave Life Sciences: Can RNA Editing Justify the Cash Burn Before the Runway Ends?

Barchart Research What to Expect from WVE Earnings WVE Generated July 29, 2026 Current Price $5.81 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.76% Wave Life Sciences: Can RNA Editing...

WVE : 5.24 (+3.87%)
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 5.24 (+3.87%)
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of...

WVE : 5.24 (+3.87%)
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing ...

WVE : 5.24 (+3.87%)
Eco Wave Power Featured for Second Time in NVIDIA Founder and CEO Jensen Huang's GTC Keynote, as Company Advances Taiwan Wave Energy Project

TAIPEI, Taiwan , June 2, 2026 /PRNewswire/ -- Eco Wave Power Global AB (publ)  (NASDAQ: WAVE), a leading onshore wave energy technology company, today announced that its technology was featured...

WAVE : 7.24 (+0.84%)
WVE : 5.24 (+3.87%)
Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 5.24 (+3.87%)

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 5.76
2nd Resistance Point 5.59
1st Resistance Point 5.42
Last Price 5.24
1st Support Level 5.08
2nd Support Level 4.91
3rd Support Level 4.74

See More

52-Week High 21.73
Fibonacci 61.8% 15.34
Fibonacci 50% 13.37
Fibonacci 38.2% 11.40
Last Price 5.24
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.